CLINICAL STUDY

The effect of hemodialysis on ocular changes in patients with the end-stage renal disease

Guijiang Suna, Rui Haoa, Longli Zhangc, Xueying Shic, Kaiwen Heic, Lijie Dongc, Fang Wei,a
Ali Jianga, Bo Lia, Xiaorong Li and Yifeng Ke3

aDepartment of Kidney Disease and Blood Purification Treatment, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China; Tianjin Eye Hospital, Tianjin Key Laboratory of Ophthalmology and Vision Science, Nankai University Eye Hospital, Clinical College of Ophthalmology, Tianjin Medical University, Tianjin, China; 3Tianjin Medical University Eye Hospital, Tianjin Medical University Eye Institute, Tianjin, China

ABSTRACT

Background: Numerous metabolic parameters can be changed during hemodialysis in the end-stage renal disease (ESRD) caused by systemic diseases, such as diabetes mellitus, hypertension. Some ocular parameters also can be variable due to the changes after hemodialysis. This study evaluates the effects of ocular parameters, including best-corrected visual acuity (BCVA), intraocular pressure (IOP), central macular thickness (CMT), subfoveal choroidal thickness (SFCT), retinal arteriolar caliber (RAC), retinal venular calibre (RVC), in ESRD patients following hemodialysis.

Materials and methods: Two-hundred and two ESRD patients were recruited resulting in 404 eyes evaluations. All patients underwent hemodialysis in the Dialysis Unit of the Second Hospital of Tianjin Medical University. BCVA, CMT, IOP, SFCT, RAC and RVC were evaluated before and after hemodialysis. Systemic parameters were collected such as age, body weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), duration of hemodialysis, body weight changes, high density lipoprotein cholesterol (HDLC), low density lipoprotein cholesterol (LDLC), very low density lipoprotein cholesterol (VLDLC), glycosylated hemoglobin (HbA1c).

Results: The causes of ESRD patients included chronic glomerulonephritis (n = 65), diabetes mellitus (n = 60), hypertensive nephrosclerosis (n = 37), and other causes (n = 40). In our study, BCVA (p = .817), CMT (p = .252) and IOP (p = .978) did not significantly change after hemodialysis. SFCT significantly decreased from 254.29 ± 69.36 μm to 235.54 ± 659.90 μm (p = .002) following hemodialysis. SFCT changes were significantly correlated with SBP (p = .042) and body weight changes (p = .044). The RAC and RVC were dilated significantly (p = .033, p = .007). RVC changes were correlated with baseline DBP (p = .003), HDLC (p = .009), LDLC (p = .004) and changes in DBP (p = .037) and body weight (p = .001).

Conclusion: Hemodialysis can affect various ocular parameters including SFCT, RAC and RVC, which changed significantly following hemodialysis. Whereas BCVA, IOP and CMT did not change after hemodialysis in ESRD patients. The systemic compensatory mechanisms of the changes in SBP, DBP, body weight following hemodialysis need further study.

Abbreviations: BCVA: Best-corrected visual acuity; IOP: intraocular pressure; CMT: central macular thickness; SFCT: subfoveal choroidal thickness; RAC: retinal arteriolar caliber; RVC: retinal venular caliber; ESRD: end-stage renal disease; HD: hemodialysis; SBP: Systolic blood pressure; DBP: diastolic blood pressure; HDLC: high density lipoprotein cholesterol; LDLC: low density lipoprotein cholesterol; VLDLC: very low density lipoprotein cholesterol; HbA1c: glycosylated hemoglobin

Introduction

Renal disease, particularly the end-stage renal disease (ESRD), is a costly and disabling condition with a high mortality rate [1]. Patients with ESRD are generally treated using a blood-filtration mechanism, such as hemodialysis. During this treatment, numerous metabolic parameters can be changed, especially blood urea, sodium, potassium and blood glucose levels. These fluctuations result in changes in blood vessels and extracellular fluids [2]. Meanwhile, some ocular parameters can also be variable due to these changes in ESRD patients. However, the changes of
ocular parameters vary. It has been reported that best corrected visual acuity (BCVA) improves after a single hemodialysis session [3]. Some research indicated central macular thickness (CMT) remain unchanged [2] or even decreased [4] after hemodialysis. Other study have reported that subfoveal choroidal thickness (SFCT) decreased after a single hemodialysis [5]. Additionally, various studies have shown IOP to increase [6], decrease [2] or remain unchanged [7]. It also reported that retinal arteriole caliber did not change, but retinal venules dilated after hemodialysis [8]. Moreover, most of the reports were small-scale study and few reports had compared ocular parameter changes with hemodialysis in different causes of ESRD.

Since the effects of hemodialysis on ocular parameters remain unclear, our study examines a large population with the short-term changes in ophthalmologic findings before and after a single hemodialysis session. The relationships between these changes and systemic parameters (e.g., body weight, SBP and DBP,) are evaluated. Furthermore, the effects of ocular parameters are evaluated and compared in patients with different causes of ESRD.

**Methods**

This prospective, cross-sectional study included 404 eyes of 202 patients with stage 5 ESRD who underwent maintenance hemodialysis in the Second Hospital of Tianjin Medical University from September 2014 to July 2017. Informed consent was obtained from all subjects, and the study conducted adhered to the Declaration of Helsinki. Institutional review board approval was also obtained from the Second Hospital of Tianjin Medical University.

All the patients in this study underwent three 4-h hemodialysis sessions each week for at least 3 months. The patients, who were less than 18-year-old and more than 75-year-old, had pregnancy, malignant tumor, infective disease, immunological disease, were eliminated. The patients with ocular disease that would interfere with ocular examination and measurement, such as macular degeneration, vitreous hemorrhage, ocular trauma and any other ocular surgery, laser therapy or intraocular injection within 3 months of enrollment were excluded. The patients with smoking habit were also excluded.

Fresenius 4008s dialysis machine (Fresenius Medical Care AG & Co. KGaA, Bad Homburg, Germany) was used with Polysulfone membrane dialyzer and low molecular weight heparin as an anticoagulant. The bicarbonate in bipolar reverse osmosis water used with a dialysate flow rate of 500 mL/min and blood flow rate of 200–300 mL/min. Predialytic and post-dialytic body weight were measured in each patient. SBP and DBP were measured during hemodialysis. Other systemic parameters were recorded such as age, HbA1c, duration of hemodialysis, HDLC, LDLC, VLDLC and blood glucose.

All the patients underwent a detailed ophthalmologic examination before and after hemodialysis. BCVA was obtained using retinoscopy optometry and IOP was measured by using tonometer (Tonopachy NT-530P, Nidek Co., LTD., Tokyo, Japan), CMT and SFCT were administrated using RTVue SD-OCT system (RTVue-XR 100 Avanti software v.6.1, Optovue, Inc., Fremont, CA, USA). Fundus photograph was obtained using a digital non-mydriatic retinal camera (CR-DGi; Canon, Tokyo, Japan).

Retinal arteriolar caliber (RAC) and retinal venular caliber (RVC) were measured in terms of retinal fundus photographs. These photographs were taken using a digital non-mydriatic retinal camera after dilating the pupils with 1% tropicamide. Two retinal images of each eye were obtained, one centered on the optic disc and another centered on fovea. The analysis of image used a computer-based program, Interactive Vessel Analysis software (IVAN) program (University of Wisconsin, US), to measure retinal vascular caliber [9]. Retinal vascular caliber was measured through a specified zone of 1 disc diameter away from the optic disc margin. Based on the revised Knudtson-Parr-Hubbard formula, retinal arteriolar and venular calibers were summarized as RAC and RVC, respectively [10]. Reproducibility of retinal vascular measurements was high, with intra-grader intraclass correlation coefficients [95% confidence interval] 0.98 (0.97–0.99) for RAC and 0.94 (0.92–0.96) for RVC.

**Statistical analysis**

Collected outcomes were analyzed using SPSS v.17.0 for Windows (SPSS, Inc., Chicago, IL, USA). The normality of the distribution of data was determined using the Kolmogorov–Smirnov test. All continuous data were normally distributed. Descriptive statistics were presented as mean ± SD. For continuous data, the ocular parameters before and after dialysis were compared with Student’s paired t-test. Pearson’s correlation coefficient test was utilized to compare the correlation of ocular parameters and systemic parameters in the hemodialysis period. A result was considered significant if the p values were <.05.
Results
A total of 202 patients (109 male and 93 female patients) were enrolled, resulting in 404 eye examinations. The general and systemic parameters are summarized in Table 1. Average age of all patients was 54.76 ± 11.10 years and subjects had been undergoing maintenance hemodialysis for a mean period of 75.24 ± 66.04 months. Mean HbA1c in hemodialysis patients combined with DM was 7.33%±1.30%. The mean body weight was 66.00 ± 11.98 kg. The average SBP and DBP in hemodialysis patients were 140.54 ± 24.93 mmHg and 80.84 ± 14.67 mmHg, respectively. The mean HDLC, LDLC and VLDLC in hemodialysis patients were 0.86 ± 0.30 mmol/L, 2.37 ± 0.71 mmol/L and 0.80 ± 0.41 mmol/L, respectively. The causes of ESRD patients were summarized in Table 2, These causes include chronic glomerulonephritis (n = 65), diabetes (n = 60), hypertensive nephrosclerosis (n = 37) and other causes (n = 40).

For systemic changes, the mean body weight decreased significantly from 66.00 ± 11.98 kg to 63.15 ± 9.42 kg after hemodialysis (p < .001). SBP and DBP also decreased significantly following the hemodialysis; the differences were 20.13 ± 16.06 mmHg and 12.57 ± 11.87 mmHg, respectively (p < .001). Systemic findings are shown in Table 3.

For ophthalmic findings, in general, the mean SFCT decreased significantly from 254.29 ± 69.36 µm to 235.54 ± 659.90 µm (p = .002) after hemodialysis. The RAC and RVC dilated remarkably from 139.37 ± 33.43 µm, 219.15 ± 49.46 µm to 145.71 ± 38.95 µm, 231.73 ± 43.43 µm (p = .033, p = .007), respectively. The SFCT, RAC and RVC had significant changes in all patients group, chronic glomerulonephritis group, diabetes mellitus group, hypertension group and other causes group following the hemodialysis except for the RVC in other causes group (p = .132). There were no significant difference in BCVA, IOP and CMT in all patients group, chronic glomerulonephritis group, hypertension group and other causes group after hemodialysis. While the BCVA and CMT were significantly changed in diabetes mellitus group following the hemodialysis (p = .042, p = .04, respectively) (Table 4).

An analysis was performed to determine if hemodialysis-induced changes in SFCT, RVC, RAC were correlated with baseline age, duration of hemodialysis, body weight, ultrafiltration rate, blood glucose, HDLC, LDLC, VLDLC and the change in SBP, DBP and body weight. The results indicated that changes in SFCT positively correlated with a body weight change (p = .044) and baseline SBP (p = .042) (Table 5). RAC changes correlated negatively with all systemic parameters (Table 6). While the changes in RVC were markedly correlated with baseline DBP (p = .003), HDLC (p = .009), LDLC (p = .004), DBP change (p = .037) and body weight change (p = .001) (Table 7).

Discussion
The prevalence of ESRD is increasing due to the ascending incidence of risk disease for ESRD, such as diabetes, metabolic syndrome and hypertension [11]. The main etiology for ESRD is variable and controversial. In the recent study, Oh et al. reported glomerulonephritis; diabetic nephropathy; hypertensive nephropathy; polycystic kidney disease were the most common causative diseases in descending order [12]. While Chelala and Tow showed that diabetic nephropathy was the leading risk disease during the chronic kidney disease [2,8].

Table 1. The general and systemic parameters of 202 patients before HD.

| Parameter | Mean ± SD | Range |
|-----------|-----------|-------|
| Age (years) | 54.76 ± 11.10 | 26–72 |
| HbA1c (%) | 7.33 ± 1.30 | 5.5–10.2 |
| Duration of HD (months) | 75.24 ± 66.04 | 4–485 |
| Body weight (kg) | 66.00 ± 11.98 | 40.2–100.4 |
| Body mass index (kg/m²) | 23.77 ± 3.52 | 16.35–33.54 |
| SBP (mmHg) | 140.54 ± 24.93 | 76–194 |
| DBP (mmHg) | 80.84 ± 14.67 | 48–114 |
| HDLC (mmol/L) | 0.86 ± 0.30 | 0.31–1.81 |
| LDLC (mmol/L) | 2.37 ± 0.71 | 1.16–4.37 |
| VLDLC (mmol/L) | 0.80 ± 0.41 | 0.16–1.91 |
| Blood glucose (mmol/L) | 5.82 ± 2.52 | 3.27–20.77 |

HbA1c: glycylated hemoglobin; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; HDLC: high density lipoprotein cholesterol; LDLC: low density lipoprotein cholesterol; VLDLC: very low density lipoprotein cholesterol; HD: hemodialysis.

Table 2. The causes for ESRD in 202 hemodialysis patients.

| Disease | n | % |
|---------|---|---|
| CGN | 65 | 25.79 |
| DM | 60 | 23.81 |
| Hypertension | 37 | 14.68 |
| PKD | 9 | 3.57 |
| Lupus nephritis | 7 | 2.78 |
| RC in nephrectomized patient | 4 | 1.59 |
| CIN | 6 | 2.38 |
| Oxalosis | 5 | 1.98 |
| FSG | 2 | 0.79 |
| Total | 202 | 100 |

CGN: chronic glomerulonephritis; DM: Diabetes Mellitus; PKD: polycystic kidney disease; RC: Renal carcinoma; CIN: chronic interstitial nephritis; FSG: focal segmental glomerulosclerosis.

Table 3. Systemic findings before and after hemodialysis treatment.

| Parameter | Pre-HD | Post-HD | Changes | p Value |
|-----------|--------|--------|---------|---------|
| Body weight (kg) | 66.00 ± 11.98 | 63.15 ± 9.42 | 3.12 ± 1.07 | <.001 |
| SBP (mmHg) | 140.54 ± 24.93 | 118.49 ± 21.11 | 20.13 ± 16.06 | <.001 |
| DBP (mmHg) | 80.84 ± 14.67 | 67.41 ± 12.63 | 12.57 ± 11.87 | <.001 |

SBP: Systolic blood pressure; DBP: Diastolic blood pressure.
Table 4. Effect of hemodialysis on ocular changes.

|                      | Pre-HD | Post-HD | p Value |
|----------------------|--------|---------|---------|
| All patients         |        |         |         |
| BCVA (LogMAR)        | 0.66 ± 0.32 | 0.66 ± 0.31 | .817    |
| IOP (mmHg)           | 14.17 ± 3.16 | 14.95 ± 2.74 | .978    |
| CMT (µm)             | 255.72 ± 35.29 | 258.19 ± 48.26 | .252    |
| SFCT (µm)            | 253.29 ± 69.36 | 235.54 ± 59.90 | .002    |
| RAC (µm)             | 139.37 ± 33.43 | 145.71 ± 38.95 | .033    |
| RVC (µm)             | 219.15 ± 49.46 | 233.73 ± 43.43 | .007    |
| Chronic glomerulonephritis |        |         |         |
| BCVA (LogMAR)        | 0.59 ± 0.35 | 0.62 ± 0.44 | .458    |
| IOP (mmHg)           | 16.33 ± 3.18 | 15.98 ± 3.05 | .229    |
| CMT (µm)             | 237.58 ± 46.24 | 243.12 ± 51.12 | .322    |
| SFCT (µm)            | 244.29 ± 51.34 | 228.54 ± 53.59 | .01     |
| RAC (µm)             | 133.37 ± 40.43 | 142.71 ± 46.95 | .02     |
| RVC (µm)             | 213.75 ± 42.76 | 227.23 ± 46.89 | .02     |
| Diabetes Mellitus    |        |         |         |
| BCVA (LogMAR)        | 0.72 ± 0.57 | 0.78 ± 0.46 | .042    |
| IOP (mmHg)           | 12.32 ± 2.39 | 12.96 ± 1.85 | .371    |
| CMT (µm)             | 298.07 ± 57.77 | 280.15 ± 60.12 | .040    |
| SFCT (µm)            | 277.31 ± 67.38 | 253.24 ± 71.06 | .001    |
| RAC (µm)             | 142.12 ± 25.45 | 150.36 ± 29.17 | .03     |
| RVC (µm)             | 228.87 ± 46.82 | 245.42 ± 44.20 | .005    |
| Hypertension         |        |         |         |
| BCVA (LogMAR)        | 0.61 ± 0.36 | 0.59 ± 0.29 | .394    |
| IOP (mmHg)           | 15.53 ± 2.19 | 15.48 ± 2.05 | .316    |
| CMT (µm)             | 250.18 ± 41.24 | 254.82 ± 32.62 | .614    |
| SFCT (µm)            | 253.29 ± 71.53 | 230.54 ± 74.62 | .001    |
| RAC (µm)             | 133.53 ± 23.42 | 142.16 ± 27.52 | .02     |
| RVC (µm)             | 211.77 ± 55.82 | 221.42 ± 60.18 | .01     |
| Other causes         |        |         |         |
| BCVA (LogMAR)        | 0.50 ± 0.26 | 0.56 ± 0.28 | .214    |
| IOP (mmHg)           | 13.83 ± 2.59 | 13.68 ± 3.05 | .646    |
| CMT (µm)             | 245.58 ± 33.24 | 248.12 ± 32.12 | .532    |
| SFCT (µm)            | 250.29 ± 61.34 | 233.54 ± 73.59 | .02     |
| RAC (µm)             | 141.53 ± 23.42 | 146.16 ± 27.52 | .11     |
| RVC (µm)             | 222.57 ± 55.82 | 235.42 ± 50.20 | .015    |

*BCVA and CMT have significant difference after HD in Diabetics Mellitus patients.

**Table 5. Determinants of subfoveal choroidal thickness changes.**

| Factors               | Subfoveal choroidal thickness change | p Value |
|-----------------------|-------------------------------------|---------|
|                      | Correlation | 95% CI (lower, upper) |         |
| Age                   | 0.069       | (−0.246, 0.250)       | .59     |
| Hemodialysis duration | −0.078      | (−0.308, 0.212)       | .543    |
| Body weight (kg)      | −0.167      | (−0.381, 0.048)       | .192    |
| Baseline SBP          | −0.243      | (−0.506, 0.01)        | .042    |
| Baseline DBP          | −0.211      | (−0.466, 0.098)       | .097    |
| Body weight change    | −0.255      | (−0.457, −0.017)      | .044    |
| SBP change            | −0.117      | (−0.256, −0.11)       | .215    |
| DBP change            | 0.167       | (0.032, 0.293)        | .127    |
| Ultrafiltration rate  | −0.035      | (−0.076, 0.54)        | .544    |
| HDLC (mmol/L)         | 0.047       | (−0.249, 0.276)       | .715    |
| LDLC (mmol/L)         | 0.103       | (−0.164, 0.404)       | .423    |
| VLDLC (mmol/L)        | 0.049       | (−0.029, 0.322)       | .704    |
| Blood glucose (mmol/L)| −0.21       | (−0.363, 0.018)       | .097    |

*Positive correlation with subfoveal choroidal thickness.

**Table 6. Determinants of central retinal arteriolar caliber changes.**

| Retinal arteriolar caliber change | Factors | Correlation | 95% CI (lower, upper) | p Value |
|----------------------------------|---------|-------------|-----------------------|---------|
| Age                              | −0.003  | (−0.288, 0.492) | .964    |
| Hemodialysis duration            | 0.388   | (0.219, 0.605) | .182    |
| Body weight (kg)                 | 0.001   | (−0.294, 0.248) | .994    |
| Baseline SBP                     | −0.194  | (−0.494, 0.111) | .128    |
| Baseline DBP                     | 0.366   | (0.095, 0.578) | .003    |
| Body weight change               | 0.423   | (0.234, 0.601) | .001    |
| SBP change                       | −0.133  | (−0.396, 0.158) | .745    |
| HDLC (mmol/L)                    | 0.287   | (0.159, 0.400) | .003    |
| Ultrafiltration rate             | −0.105  | (−0.209, 0.094) | .394    |
| HDL cholesterol (mmol/L)         | −0.327  | (0.072, 0.598) | .009    |
| LDL cholesterol (mmol/L)         | −0.362  | (−0.499, −0.115) | .004    |
| VLDLC cholesterol (mmol/L)       | 0.032   | (−0.317, 0.292) | .804    |
| Blood glucose (mmol/L)           | 0.202   | (−0.029, 0.377) | .112    |

*Positive correlation with retinal arteriolar caliber.

**Table 7. Determinants of central retinal venular caliber changes.**

**Table 8. Factors associated with changes in subfoveal choroidal thickness.**

**Table 9. Factors associated with changes in central retinal arteriolar caliber.**

**Table 10. Factors associated with changes in central retinal venular caliber.**

During the process of ESRD, Caucasian preferred high caloric diet compared with Asian, leading to a high prevalence of diabetes and metabolic syndrome disease.

The choroid has a rich vascular network and highest blood supply per organ area. During a hemodialysis session, numerous metabolic parameters change. Ultrafiltration removes excess fluid from plasma, which leads to an increasing in the plasma protein concentration. Blood volume depletion is equilibrated by vascular refilling from the interstitial and intracellular space [13]. This may lead to the change in choroidal thickness (CT) following a hemodialysis session. Jung et al. studied on 28 eyes in 19 patients with ESRD and reported that SFCT increased following a hemodialysis session and was correlated with decline in SBP [14]. They proposed that the increase in SFCT might be associated with the choroidal autoregulatory control of ocular hemodynamics, shifting of fluid and molecules between the plasma.
and choroidal interstitium. However, there were conflicting results on the effects of SFCT following a hemodialysis session. Chang et al. recruited 31 patients resulting in 54 eyes and showed that choroidal thickness was reduced in all areas following a hemodialysis session. The reduction in choroidal thickness was correlated with body weight loss, serum osmolarity and SBP [15]. Ishibazawa et al. analyzed 41 patients with ESRD and found the SFCT decreased in all eyes after hemodialysis [16]. Chen and Celikay also showed that choroidal thickness was decreased in the patients with ESRD following a hemodialysis session [5,17]. Our results indicated that the changes in SFCT were reduced remarkably following a hemodialysis session. The reduction in choroidal thickness was correlated with body weight loss and baseline SBP. According to our observation on these studies, only one paper showed SFCT was increased whereas all the other papers have demonstrated reducing SFCT after hemodialysis session. The difference between these conflicting results may be related to the methodology used to measure choroidal thickness and the demographic variation of the populations in different study groups [17]. In addition, the mechanism of the SFCT thinning may be the result of the increase in choroidal vascular and nonvascular smooth muscle contraction which was due to the activation of the sympathetic autonomic nervous system. It is well known that choroidal circulation was controlled primarily by the extrinsic autonomic system. Sympathetic activation triggered by blood volume depletion might cause choroidal vascular and nonvascular smooth muscle constriction [18], which led to a decrease in CT.

Another major finding of this study is that the hemodialysis results in dilatation of the retinal venules and arterioles. In present study, the RAC and RVC were significantly increasing after the hemodialysis. When all possible variables were taken into account, the RVC changes between pre and post dialysis were correlated with DBP, LDLC, HDLC and changes in body weight and DBP. Although the mean RAC rose significantly after the hemodialysis, the change in RAC did not correlate with any systemic parameters. This result was partly different from the previous study. Tow et al. analyzed on 24 patients and showed that the mean RVC increased significantly. After dialysis, the change in RVC was correlated only with the body weight change. However, the mean RAC did not change significantly after the hemodialysis [4]. We are of the opinion that the conflicting results of RAC were due to the size of the different population. The previous study had a small sample size compared with our study. We thought that might be the key factor for the different results.

The mechanism of the dialysis-associated vasodilation is not clear. Usually, endothelium-dependent vasodilatation was thought to be the major vasodilatation mechanism in ESRD patients [19]. Endothelium-dependent dilatation in response to flow-mediated shear stress is impaired in the resistant vasculature from patients with ESRD and finally result in contraction of resistance vasculature due to blunted blood flow and the lack of nitric oxide (NO) contribution [20]. However, dilatation of the retinal microvasculature after dialysis is thought to occur secondary to the release of vasoactive factors, such as nitric oxide, nitrotyrosine, Asymmetric dimethylarginine (ADMA), heat shock proteins, in response to the reduced intravascular volume [21]. For example, asymmetric dimethylarginine, an inhibitor of nitric oxide synthase, accumulates in renal failure [22]. The elevated levels of ADMA would decrease NO production. However, it was removed by dialysis, resulting in enhanced nitric oxide production and consequent vasodilatation. And so did the nitrotyrosine [20].

In our study, BCVA and CMT did not change remarkably following a single hemodialysis session except DM groups. BCVA and CMT changes were insignificantly correlated with any systemic parameters (data not show). This result is supported by Chelala’s study [2]. They analyzed on 49 eyes from 49 chronic kidney-disease patients and demonstrated that neither BCVA nor CMT significantly changed after the hemodialysis. Our study also revealed that the mean BCVA and CMT were reduced only in diabetic ESRD patients after the hemodialysis (Table 4). Diabetic patients were prone to visual disturbance such as decreasing VA due to retinopathy. These effects were more common in diabetic hemodialysis patients [23]. Nevertheless, the previous results of BCVA changes varied in diabetic hemodialysis patients. Ghasemi reported osmotic changes during hemodialysis, induced by hyperglycemia before the starting of insulin therapy, played an important role in lens overhydration by sorbitol accumulation [24]. Tai et al. studied groups of poorly controlled diabetic patients and reported that the alteration in refractive index of the lens was responsible for the refractive changes of the eye [25]. On the other hand, Wiemer et al. reported that no significant correlations were found between changes in blood glucose and refractive states of the cornea and lens in diabetic patients [26]. The BCVA reduction may due to a series of happenings caused by the hemodialysis microvascular changes, including ocular hypotension, decrease in zonular tension, shallowing of the anterior chamber, thickening of the lens and
finally a myopic shift in refractive power of the eye [27]. There are also some other papers showing that BCVA reduction or loss after the hemodialysis was caused by the ischemic optic neuropathy [28,29]. In addition, decrease in CMT during hemodialysis has also been involved in the hemodialysis microvascular changes [30]. Each 50 μm changes in retinal thickness caused 0.15 D changes in refractive error, this may explain the decrease in CMT induced BCVA reduction during hemodialysis session [22].

The IOP change following hemodialysis remains controversial. Many conflicting IOP results have been published on the effects of hemodialysis. Çelikay et al. concluded that IOP did not significantly change after hemodialysis in ESRD patients [17]. Our study also supports the above-mentioned findings. However, Chelala et al. have demonstrated a slight but significant decrease in IOP with hemodialysis that was independent of ESRD cause. IOP change was predominantly associated with serum albumin levels and weight changes [2]. Yang and Jung reported that the mean IOP decreased significantly after hemodialysis in chronic renal failure patients [3,31]. The proposed mechanism of IOP change was rarely reported. Tokuyama et al. reported that IOP reduction was related to ultrafiltration rate by the mean of albumin level. The increasing oncotic pressure caused by ultrafiltration leads to a decline in IOP at the end of dialysis. IOP change is greater with a higher plasma albumin level and degree of ultrafiltration [32]. While the other study was proposed by Broekema, who suggested that despite a decrease in blood osmotic pressure, other regulatory forces prevent significant fluctuations in IOP during the hemodialysis [33].

In conclusion, our study found that hemodialysis can affect various ocular parameters, specifically SFCT, RAC and RVC, which changed significantly following the hemodialysis. The changes in SBP, DBP, body weight following hemodialysis may be a consequence of systemic compensatory mechanisms. Additionally, large-scale randomized studies are needed to determine the effect of hemodialysis on SFCT, retinal vasodilatation, the relationship between SFCT, RAC, RVC and systemic parameters. Although BCVA, IOP and CMT did not change post-hemodialysis in ESRD patients in this study, the ongoing study is needed to further determine the controversial result.

**Ethical approval and consent to participate**

This study was approved by the Ethics Committee of the Second Hospital of Tianjin Medical University.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

Yifeng Ke was supported by Tianjin Natural Science Foundation [Grant number: 16JCQNJC12700] and National Natural Science Foundation of China [Grant number: 81500745]; Rui Hao was supported by National Natural Science Foundation of China [Grant number: 81800861]; Lijie Dong was supported by National Natural Science Foundation of China [81570872] and Tianjin Municipal Science and Technology Commission Grants [15JCYBJC24900].

**Data availability**

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

**References**

[1] Bethesda, MD. System USRD USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013.

[2] Chelala E, Dirani A, Fadlallah A, et al. Effect of hemodialysis on visual acuity, intraocular pressure, and macular thickness in patients with chronic kidney disease. Clin Ophthalmol. 2015;9:109–114.

[3] Jung JW, Yoon MH, Lee SW, et al. Effect of hemodialysis (HD) on intraocular pressure, ocular surface, and macular change in patients with chronic renal failure. Effect of hemodialysis on the ophthalmologic findings. Graefes Arch Clin Exp Ophthalmol. 2013;251:153–162.

[4] Evans RD, Rosner M. Ocular abnormalities associated with advanced kidney disease and hemodialysis. Semin Dial. 2005;18:252–257.

[5] Chen H, Zhang X, Shen X. Ocular changes during hemodialysis in patients with end-stage renal disease. BMC Ophthalmol. 2018; 18:208.

[6] Nongpiur ME, Wong TY, Sabanayagam C, et al. Chronic kidney disease and intraocular pressure: the Singapore malay eye study. Ophthalmology. 2010;117: 477–483.

[7] Pelit A, Zumrutdal A, Akova Y. The effect of hemodialysis on visual field test in patients with chronic renal failure. Curr Eye Res. 2003;26:303–306.

[8] Tow FK, Ooi QL, Wong TY, et al. Microvascular dilatation after haemodialysis is determined by the volume of fluid removed and fall in mean arterial pressure. Kidney Blood Press Res. 2012;35:644–648.

[9] Wong TY, Knudtson MD, Klein R, et al. Computer-assisted measurement of retinal vessel diameters in the Beaver Dam Eye Study: methodology, correlation between eyes, and effect of refractive errors. Ophthalmology. 2004;111:1183–1190.

[10] Knudtson MD, Lee KE, Hubbard LD, et al. Revised formulas for summarizing retinal vessel diameters. Curr Eye Res. 2003;27:143–149.
[11] Nagata M, Ninomiya T, Doi Y, et al. Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: the Hisayama Study. Nephrol Dial Transplant. 2010;25:2557–2564.

[12] KNOW-ESRD. KoreaN cohort study for outcome in patients with chronic kidney disease: design and methods. BMC Nephrol. 2014;15:80.

[13] Taal MW, Brenner BM, Rector FC. Hemodialysis. In: Chertow GM, Marsden PA, Skorecki K, Yu AS, editors. Brenner & Rector’s the kidney. 9th ed. Philadelphia, PA, USA: Saunders Elsevier; 2012.

[14] Jung JW, Chin HS, Lee DH, et al. Changes in subfoveal choroidal thickness and choroidal extravascular density by spectral domain optical coherence tomography after haemodialysis: a pilot study. Br J Ophthalmol. 2014;98:207–212.

[15] Chang IB, Lee JH, Kim JS. Changes in choroidal thickness in and outside the macula after hemodialysis in patients with end-stage renal disease. Retina. 2017;37:896–905.

[16] Ishibazawa A, Nagaoka T, Minami Y, et al. Choroidal thickness evaluation before and after hemodialysis in patients with and without diabetes. Invest Ophthalmol Vis Sci. 2015;56:6534–6541.

[17] Çelikay O, Çalışkan S, Biçer T, et al. The acute effect of hemodialysis on choroidal thickness. J Ophthalmol. 2015;2015:528681.

[18] Kur J, Newman EA, Chan-Ling T. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Prog Retinal Eye Res. 2012;31:377–406.

[19] Triggle CR, Samuel SM, Ravishankar S, et al. The endothelium: influencing vascular smooth muscle in many ways. Can J Physiol Pharmacol. 2012;90:713–738.

[20] Luksha N, Luksha L, Carrero JJ, et al. Impaired resistance artery function in patients with end-stage renal disease. Clin Sci. 2011;120:525–536.

[21] Noris M, Benigni A, Boccardo P, et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int. 1993;44:445–450.

[22] Kang ES, Tevlin MT, Wang YB, et al. Haemodialysis hypotension: interaction of inhibitors, INOS, and the interdialytic period. Am J Med Sci. 1999;317:9–21.

[23] de Fine ON, Siersma V, Almind GJ, et al. Prevalence and progression of visual impairment in patients newly diagnosed with clinical type 2 diabetes: a 6-year follow up study. BMC Public Health. 2011;11:80.

[24] Ghasemi H, Afshar R, Zerafatjou N, et al. Impact of hemodialysis on visual parameters in patients with end-stage renal disease. Iran J Kidney Dis. 2012;6:457–463.

[25] Tai MC, Lin SY, Chen JT, et al. Sweet hyperopia: refractive changes in acute hyperglycemia. Eur J Ophthalmol. 2006;16:663–666.

[26] Wiemer NG, Dubbelman M, Ringens PJ, et al. Measuring the refractive properties of the diabetic eye during blurred vision and hyperglycaemia using aberrometry and Scheimpflug imaging. Acta Ophthalmol. 2009;87:176–182.

[27] Furushima M, Imaizumi M, Nakatsu K. Changes in refraction caused by induction of acute hyperglycemia in healthy volunteers. Jpn J Ophthalmol. 1999;43:398–403.

[28] Chang YS, Weng SF, Chang C, et al. Risk of nonarteritic anterior ischemic optic neuropathy following end-stage renal disease. Medicine (Baltimore). 2016;95:e3174.

[29] Purgert RJ, Peralta E, McClelland CM, et al. Combined anterior ischemic optic neuropathy and hemiretinal artery occlusion during hemodialysis. Can J Ophthalmol. 2015;50:e19–e21.

[30] Theodossiadis PG, Theodoropoulou S, Neamontou G, et al. Hemodialysis-induced alterations in macular thickness measured by optical coherence tomography in diabetic patients with end-stage renal disease. Ophthalmologica. 2012;227:90–94.

[31] Yang SJ, Han YH, Song GI, et al. Changes of choroidal thickness, intraocular pressure and other optical coherence tomographic parameters after haemodialysis. Clin Exp Optom. 2013;96:494–499.

[32] Tokuyama T, Ikeda T, Ishikawa H, et al. Marked decrease in intraocular pressure in a neovascular glaucoma patient during hemodialysis. Jpn J Ophthalmol. 1997;41:101–103.

[33] Broekema N, van Bijsterveld OP, de Bos Kuil RJ. Intraocular pressure during hemodialysis. Ophthalmologica. 1988;197:60–64.